

The background is a dark blue gradient. In the corners, there are decorative white circuit-like lines with small circles at the end, resembling a network or data flow diagram.

Neonatal Abstinence: The epidemic

Its Impact on All of Us

Michelle Bode MD, MPH

Neonatologist Crouse Hospital


Assistant Professor Pediatrics SUNY Upstate

Objectives & Disclosure Statement

- 1) The participant will be able to define the role of maternal opioid use and the risk of neonatal abstinence
- 2) The participant will be able to define neonatal abstinence and its impact on maternal newborn bonding
- 3) The participant will understand the magnitude of NAS epidemic in central NY and the US.

Dr. Michelle Bode has no conflicts of interest or financial relationships with any commercial entities.

PREGNANCY AND PRESCRIPTION OPIOID ABUSE AMONG SUBSTANCE ABUSE TREATMENT ADMISSIONS



Martin, C.E., et al. Recent trends in treatment admissions for prescription opioid abuse during pregnancy. *Journal of Substance Abuse Treatment*. 2014.

For the Mom To Be

- Referral to treatment programs needs to be expedited
- Data is conflicting as to “BEST Evidence” for “MOM” management
 - Should we DETOX during pregnancy
 - Should we recommend “MAINTENANCE “ therapy
 - Is Naloxone safe in pregnancy?
- Care & Treatment needs to look at the DYAD

•THE MAGIC WINDOW OF OPPORTUNITY

NEONATAL ABSTINENCE SYNDROME

A constellation of typical signs and symptoms that occur in infants that have been exposed in utero, therefore have developed “dependence”, to certain illicit or prescription medications

NAS NATIONWIDE

NAS Incidence in the U.S.



Every hour,
1 BABY
is born
suffering
from opiate
withdrawal.



Patrick, S. W. et al. JAMA 2012;307:1934-1940

NAS NATIONWIDE INCIDENCE

- Tolia VN, et al. Increasing Incidence of the Neonatal Abstinence Syndrome in US Neonatal ICU's. *NEJM* 2015.
- Pediatrix Database

Year	2004	2013
Incidence	7/1000	27/1000

THE CNY EXPERIENCE- BIRTH CERTIFICATE DATA

	2006	2008	2010	2012	2013	2014	2015
Total Live Births ≥500 grams	19304	19693	18918	19358	18919	18260	18211
Illicit Drug Use during pregnancy	2.1% (403)	2.5% (496)	3.2% (600)	3.5% (669)	4.7% (889)	5.3% (967)	5.9% (1074)

INCIDENCE

	CNY Birth Not Born at Crouse	Born at Crouse	Incidence (exposed /1000 livebirths)
2012	3.2%	4.5%	35
2013	4.2%	6.4%	47
2014	4.5%	7.7%	52
2015	5.3%	8.1%	59

MANAGEMENT

- Prenatal Consult with Neonatology
- Breastfeed when possible --Dispel the myth that only formula is safe now
- Comfort Measures-
 - Infant Massage
 - Quiet environment
 - Swaddling
 - Family Involvement
- Monitoring with a standard protocol
- Treatment with medications

BREASTFEEDING

Substance	OK
Methadone	Yes
Heroin	No
Prescribed Opioids: Buprenorphine (Subutex), Hydrocodone, Oxycodone, Percocet, etc	Yes
Cocaine	No

NEONATAL PHARMACOLOGIC TREATMENTS:

- Morphine
- Methadone
- Buprenorphine
- Clonidine
- Phenobarbital

WHAT'S BEST????

Infant Outcomes: Short and Long Term

- Increased risk of poor bonding, poor infant growth
- Higher risk of infant death
 - SIDS
 - Rollover accidents
 - Poisoning

HOWEVER

- Development can be normal when the infant is raised in an enriched and loving environment

ONONDAGA COUNTY RESPONSE

- Drug Task force- members include:
 - Health Commissioner
 - Medical Community- Representatives from all Hospitals and Community providers
 - Law Enforcement
 - Community Leaders
- GOALS:
 - Training of Healthcare staff to identify women and deliver early treatment
 - Develop Public Health Campaign
 - Eliminate access and availability of illicit drugs

REFERENCES

1. American Academy of Pediatrics. Neonatal Drug Withdrawal. Committee on Drugs. *Pediatrics*. Feb 2012.
2. American Academy of Pediatrics. Neonatal Drug Withdrawal. Committee on Drugs. *Pediatrics*. 1998;101:1079-1088.
3. Burgos AE, Burke BL. Neonatal abstinence syndrome. *Neoreviews*. May 2009;10(5): e222-e229.
4. Sielski LA. Neonatal opioid withdrawal. *UpToDate*. Jan 22,09;17.1
5. Osborn DA, Jeffery HE, Cole MJ. Opiate treatment for opiate withdrawal in newborn infants. *Cochrane Database of Systemic Reviews*. 2009, Issue 3.
6. Osborn DA, Jeffery HE, Cole MJ. Sedatives for opiate withdrawal in newborn infants. *Cochrane Database of Systemic Reviews*. 2009, Issue 3.
7. Johnson K, Gerada C, Greenough A. Treatment of neonatal abstinence syndrome. *Arch Dis Child Fetal Neonatal Ed*. 2003;88:F2-F5.
8. Coyle MG, Ferguson A, et al. Diluted tincture of opium (DTO) and Phenobarbital versus DTO alone for neonatal opiate withdrawal. *J Pediatr*. 2002;140:561-4.
9. Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. *Addict Dis*. 1975;2:141-158.
10. Medications and mothers milk. <http://medsmilk.com>. HalePublishing. 1992-2008.
11. Bio LL, Siu A, Poon CY. Update on the pharmacologic management of neonatal abstinence syndrome. *J Perinatology*. 2011;116:1-10.
12. Pritham UA. Breastfeeding promotion for management of neonatal abstinence syndrome. *JOGGN*. 2013;42:517-526.
13. Wexelblatt SL, Ward LP, Torok K, et al. Universal maternal drug testing in a high prevalence region of prescription opiate abuse. *J Peds*. March 2015;166(3):582-586.
14. Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal abstinence syndrome in US neonatal ICUs. *NEJM*. April 2015; downloaded from the nejm.org on May 16, 2015.